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Abstract: Higher titers of autoantibodies
have been reported in recent studies of
depressed patients. In an attempt to
investigate the presence of antiphospholipid
autoantibodies in patients with depression,
sera from both patients and healthy controls
were tested for immunoglobulin G and M
anticardiolipin and antiphosphatidylserine
autoantibodies. We tested positive sera for
antiphosphatidylserine (APSA) and anticardiolipin autoantibody (ACA) in 10 dysthymic,
19 major depressive, and 20 healthy
subjects. Tests for ACA-IgM were found to be
positive in 1 of the dysthymic patients, in 1
of the major depressives and 1 member of
the control group. Positive ACA-IgG was
found in 1 of the dysthymic patients, 1 of the
major depressives and 1 member of the
control group. Positive APSA-IgM was found

Introduction
Antibodies against phospholipids are autoantibodies
with high affinity for negatively charged phospholipids in
the inner surface of the cell membrane (1,2).
Phospholipids are also present in the serum, bound to
proteins (lipoproteins), and they play an important role in
the coagulation process (2). Antiphospholipid groups
react with negatively charged phospholipids via
phospholipid binding proteins. The most commonly
reported antiphospholipids are anticardiolipin (ACA),
antiphosphatidylserine antibodies (APSA) and the lupus
anticoagulant (LA) (3,4). These autoantibodies, ACA and
LA, mainly the Ig G isotype of anticardiolipin, have been
associated with thrombotic vascular events in
autoimmune-related disorders, as well as with recurrent

in 3 of the dysthymic patients, 3 of the major
depressives and 4 members of the control
group. Positive APSA-IgG was found in 2 of
the dysthymic patients, 2 of the major
depressives and 3 members of the control
group. There were no significant differences
in IgG, IgM-ACA and APSA between the
dysthymic and major depressive groups and
the control group. After categorizing both
groups for age and sex, no difference was
found in the frequency of ACA and APSA
positive sera between both groups, indicating
that on the basis of serology, no evidence
exists that antiphospholipid autoantibodies
might be the etiological factor for dysthymic
or major depressive disorders.
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fetal loss (5), dementia (6,7), migraine, chorea (8) and
epilepsy (9). Maes et al. (1991) have reported higher
titers of these autoantibodies in depressed subjects. They
measured antiphospholipid (anticardiolipin, antiphosphatidylserine), antinuclear antibodies in healthy controls,
minor, simple major and melancholic patients and found
that anticardiolipin antibody titers were higher in
melancholics than in healthy controls and minor
depressives, that antinuclear antibodies were found more
frequently in depressed patients than in normal
volunteers, and that there was a positive correlation
between anticardiolipin and antinuclear antibody titers
(10). In another study, Maes et al. (1992) measured the
binding index of APSA, ACA and antipartial
thromboplastin (APTA) in 22 minor, 23 simple major and

585

Antiphospholipid Autoantibodies in Depressive Disorders

20 melancholic depressives. They found a higher
expression of antiphospholipid antibodies during
depression but a much lower incidence of antibodypositive patients than in classical autoimmune disorders
(11). The aim of the present study was to clarify the
possible relationship between the presence of
antiphospholipid autoantibodies (i.e., anticardiolipin and
antiphosphatidylserine) and various depression
categories.
Material and Methods
Subjects
Twenty-nine consecutive patients with depressive
disorder and 20 normal controls were included in the
study. The patients were categorized according to the
fourth edition of the Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV) (12).
Their condition was diagnosed with the aid of the
Structured Clinical Interview for DSM-IV, clinical version
(13). Depression severity was measured using the
Hamilton Depression Rating Scale (Ham-D) (14). None of
the subjects had evidence of SLE or other autoimmunerelated disorders. Exclusion criteria for the study included
epilepsy, history of thrombosis or other vascular events,
fetal loss, or chronic medication of any type. Eighteen
depressed patients were free of psychotropic drugs for at
least one month prior to hospital admission. The others
(n=11) had been taking antidepressants. These drugs
were discontinued upon admission, and consequently
these subjects underwent a washout period of 7 days
before blood samples were collected as also done in the
study of Maes et al. (11).
Twenty voluntary healthy donors, with no history of
psychiatric or vascular events or fetal loss and with no
history of chronic medication, were age matched and
served as the control group.
Serum samples
Ten milliliters of nonheparinized venous blood was
drawn and allowed to clot at room temperature. The sera
were separated on the same day and stored at Ð20¡C
until use.
Detection
of
antiphosphatidylserine
anticardiolipin IgG and IgM

and

Antiphosphatidylserine antibodies were detected by
using the micro-ELISA technique and a Clark Laboratories
Inc. test kit. The assay wells were coated with
phosphatidylserine purified from bovine spinal cord. The
positive control, the negative control, the cut-off control
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and all the samples were diluted 1:100 with sample
diluent. 100µl of diluted controls and samples were
pipetted into the wells of microtiter strips. The plates
were incubated at room temperature (18-25¡C) for 30
minutes, and then were washed four times with washing
buffer. After this treatment, 100µl of enzyme conjugate
(horseradish peroxidase conjugated anti-IgG or anti-IgM)
was added to the wells. The plates were incubated at
room temperature (18-25¡C) for 15 minutes. The
washing procedure was repeated as described previously.
100µl of substrate solution (tetramethyl benzidine) was
added to the wells, which were then incubated at room
temperature (18-25¡C) for 15 minutes. 50µl of stopping
solution (1N H2SO4) was added to the wells. The optical
density (OD) of the controls, calibrator and samples was
read on a multiscan spectrophotometer (multiplate
autoreader EL-309) at 450nm.
The results for IgG and IgM antiphosphatidylserine
antibodies were calculated separately. A positive value
was defined as an OD sample difference higher than the
calibrator (OD calibrator for IgG: 60 arb u/ml, OD
calibrator for IgM: 60 arb u/ml).
The anticardiolipin IgG and IgM antibodies assays
were performed by substituting phosphatidylserine with
cardiolipin.
The results for IgG and IgM cardiolipin antibodies
were calculated separately. A positive value was defined
as an OD sample difference greater than the index value
( 0.90: negative, 1.10: positive).
Statistical Analysis
All statistical analysis was performed using the SPSS
7.0 statistical program (14). Comparisons were carried
out by means of the χ2 test.
Results
The depressed patients consisted of 10 dysthymic
disorder patients, 19 major depressive disorder patients,
10 of them with a single episode (7 with psychotic
features) and 9 of them recurrent. There were no
significant differences (χ2 =7.05; df: 5; p< 0.217) in age
between the study groups; mean (±SEM) of the control
group was 33.3(±2.57), that of the dysthymic disorder
group years was 43.38(±7.13), and that of the major
depressive disorder group was 30.00(±6.87), with
35.14(±5.68) for a single episode and 41.17(±6.51) years
for recurrent episodes. There were no significant
differences in the male-to-female ratios between these
groups, which were as follows: controls, 10/10; dysthymic
disorder, 6/4; major depressive disorder, 9/10.
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There were no significant differences in APSA and IgG
and IgM cardiolipin antibodies between the depressive
group and the control group. The data in the Table show
that APSA and IgG and IgM group cardiolipin antibodies
were not significantly more common in either the
depressive patient group or its subgroups compared with
the control subjects. Fifteen patients had mild depressive
symptoms, 10 had moderate symptoms and 5 had severe
depressive symptoms. There was no significant difference
between the groups in terms of positive sera for APSA
and ACA. There was no significant relationship between
age and positive ACA and APSA. There was no difference
in positive ACA and APSA between subjects who were
drug-free and those who were on psychotropic drugs
prior to admission.

there were no meaningful positive values when compared
with SLE (11).
We assessed the sera of donors, identifying them as
negative or positive and we used an index value which is
Table .

Frequency and statistical comparison of ACA-IgM, ACA-IgG,
APSA-IgM, APSA-IgG in depressive patients and control
subjects.
ACA-IgM

Dysthymics

ACA-IgG

APSA-IgM

APSA-IgG

10

10

10

10

No. tested

1

1

3

2

No. positive

1

1

3

2

No. tested

10

10

10

10

No. positive

1

-

2

2

No. tested

9

9

9

9

No. positive

-

1

1

-

No. tested

20

20

20

20

No. positive

1

1

4

3

9.740

7.232

3.052

2.701

.284

.512

.549

.609

1.170

.709

1.038

.532

.279

.400

.845

.466

.498

.042

.714

.480

.480

.837

.398

.488

Major depressives

Discussion
The last decade has produced a series of studies
documenting that depression may be associated with
impairment of the immune function (16). Some authors
have reported the presence of antinuclear antibodies in
subjects with major depression compared with normal
volunteers (10,17-19). There is a parallel between the
clinical, biochemical and immunological features of
depression and classical autoimmune disorders: (i) both
depression and autoimmune disorders tend to be
recurrent and may follow a course of alternating
exacerbations and remissions (20); (ii) autoimmune
disorders such as systemic lupus erythematosus (SLE)
show a high rate of mental manifestation and brain
reactive autoantibodies are pathogenetically relevant for
these symptoms (21), (iii) both disorders occur
frequently in females (20,22,23); (iv) the status of sex
hormones (such as estrogens) may be linked to
exacerbations in both depression (24) and SLE (25); (v)
the incidence of autoimmunity tends to increase in aged
populations (23), and the frequency and intensity of
severe depression increases with age (26,27).
In our study, we could not find any significant
relationship between the severity of illness (HDRS) and
any of the antiphospholipid autoantibody titers. There
were no significant relationships between age and
positive ACA and APSA. There were no differences in
positive ACA and APSA between subjects who were drugfree and those who were on psychotropic drugs prior to
admission. A limited number of studies have reported
that depressive patients have higher APSA and ACA titers.
In one study, higher ACA titers were found in depressive
disorders (10). In another study, Maes et al. found a
higher binding index in depressives than in controls but

single episode

recurrent

Healthy controls

Dysthymics vs.
major depressives
χ2
p value

dysthymics vs. control
χ2
p value

major depressive
vs. controls
χ2
p value

ACA-IgM: Anticardiolipin Immunoglobulin M, ACA-IgG: Anticardiolipin
Immunoglobulin G,
APSA-IgM: Antiphosphatidylserine Immunoglobulin M, APSA-IgG:
Antiphosphatidylserine Immunoglobulin p values<0.05 were considered
significant.
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used for autoimmune disorders. The differing results
might be due to this assessment method.
In conclusion, although there are a lot of similarities in
terms of clinical and laboratory findings, we do not think

there is a causal relationship between systemic immune
activation and the pathogenesis of depression. However,
studies using a larger sample should be carried out.
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